Buzo Bruno Fernando, Preiksaitis Jutta K, Halloran Kieran, Nagendran Jayan, Townsend Derek R, Zelyas Nathan, Sligl Wendy I
Tranplant Infectious Diseases, Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada.
Lung Transplant Program, Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, Canada.
Transpl Infect Dis. 2022 Dec;24(6):e13940. doi: 10.1111/tid.13940. Epub 2022 Sep 6.
Hyperammonemia syndrome (HS) is a rare post-transplant complication associated with high morbidity and mortality. Its incidence appears to be higher in lung transplant recipients and its pathophysiology is not well understood. In addition to underlying metabolic abnormalities, it is postulated that HS may be associated with Ureaplasma or Mycoplasma spp. lung infections. Management of this condition is not standardized and may include preemptive antimicrobials, renal replacement, nitrogen scavenging, and bowel decontamination therapies, as well as dietary modifications.
In this case series, we describe seven HS cases, five of whom had metabolic deficiencies ruled out. In addition, a literature review was performed by searching PubMed following PRISMA-P guidelines. Articles containing the terms "hyperammonemia" and "lung" were reviewed from 1 January 1997 to 31 October 2021.
All HS cases described in our center had positive airway samples for Mycoplasmataceae, neurologic abnormalities and high ammonia levels post-transplant. Mortality in our group (57%) was similar to that published in previous cases. The literature review supported that HS is an early complication post-transplant, associated with Ureaplasma spp. and Mycoplasma hominis infections and of worse prognosis in patients presenting cerebral edema and seizures.
This review highlights the need for rapid testing for Ureaplasma spp. and M. hominis after lung transplant, as well as the necessity for future studies to explore potential therapies that may improve outcomes in these patients.
高氨血症综合征(HS)是一种罕见的移植后并发症,发病率和死亡率都很高。其在肺移植受者中的发病率似乎更高,且其病理生理学尚未完全明确。除了潜在的代谢异常外,推测HS可能与脲原体或支原体属肺部感染有关。这种疾病的管理尚无标准化方案,可能包括预防性使用抗菌药物、肾脏替代治疗、氮清除、肠道去污治疗以及饮食调整。
在这个病例系列中,我们描述了7例HS病例,其中5例排除了代谢缺陷。此外,按照PRISMA-P指南在PubMed上进行了文献检索。对1997年1月1日至2021年10月31日期间包含“高氨血症”和“肺”的文章进行了综述。
我们中心描述的所有HS病例气道样本中支原体科检测均为阳性,移植后出现神经学异常和高氨水平。我们组的死亡率(57%)与先前病例报道的相似。文献综述支持HS是移植后的早期并发症,与脲原体属和人型支原体感染有关,且出现脑水肿和癫痫发作的患者预后较差。
本综述强调肺移植后需要快速检测脲原体属和人型支原体,以及未来研究探索可能改善这些患者预后的潜在治疗方法的必要性。